Published in BMC Psychiatry on October 05, 2013
Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia. PLoS One (2015) 0.81
Using films as a psychoeducation tool for patients with schizophrenia: a pilot study using a quasi-experimental pre-post design. BMC Psychiatry (2015) 0.75
Association between non-compliance with psychiatric treatment and non-psychiatric service utilization and costs in patients with schizophrenia and related disorders. BMC Psychiatry (2016) 0.75
Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia. Am Health Drug Benefits (2016) 0.75
Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China. BMC Health Serv Res (2015) 0.75
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45
Estimating log models: to transform or not to transform? J Health Econ (2001) 11.10
A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry (2007) 7.49
Schizophrenia and increased risks of cardiovascular disease. Am Heart J (2005) 4.90
Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv (2004) 4.16
The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry (2005) 3.92
Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry (2004) 3.26
Community care for patients with schizophrenia one year after hospital discharge. BMJ (1991) 2.74
Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69
Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care (2002) 2.68
Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry (2006) 2.49
Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res (2010) 2.09
Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv (2001) 2.02
Medical comorbidity in schizophrenia. Schizophr Bull (1996) 1.91
The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry (2010) 1.80
Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin (2007) 1.71
Continuity of care after inpatient discharge of patients with schizophrenia in the Medicaid program: a retrospective longitudinal cohort analysis. J Clin Psychiatry (2010) 1.67
Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. Schizophr Bull (2005) 1.66
An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care (2008) 1.63
Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol (2003) 1.53
Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother (2009) 1.46
A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry (2008) 1.39
Issues for the next generation of health care cost analyses. Med Care (2009) 1.32
Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull (2007) 1.30
Identifying risk factors and key strategies in linkage to outpatient psychiatric care. Am J Psychiatry (2000) 1.26
Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health (2009) 1.12
Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry (2000) 1.11
Effects of health care cost-containment programs on patterns of care and readmissions among children and adolescents. Am J Public Health (1999) 1.10
Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull (1998) 1.08
Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv (2010) 0.98
Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. Psychiatr Serv (2009) 0.96
Does medication adherence lower Medicare spending among beneficiaries with diabetes? Health Serv Res (2011) 0.95
Psychiatric rehospitalization among elderly persons in the United States. Psychiatr Serv (2008) 0.95
Do treatment restrictions imposed by utilization management increase the likelihood of readmission for psychiatric patients? Med Care (1998) 0.94
Linking inpatients with schizophrenia to outpatient care. Psychiatr Serv (1998) 0.94
Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med (2012) 0.92
Deinstitutionalization and schizophrenia in Finland: I. Discharged patients and their care. Schizophr Bull (1998) 0.91
Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res (2011) 0.90
Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences. Eur Psychiatry (2001) 0.89
Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians' perceptions of adherence vs. pharmacy claims. Int J Clin Pract (2012) 0.87
The association between timely outpatient visits and the likelihood of rehospitalization for schizophrenia patients. Am J Orthopsychiatry (2008) 0.84
Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia. Patient Prefer Adherence (2010) 0.81
Incurring greater health care costs: risk stratification of employees with bipolar disorder. Prim Care Companion J Clin Psychiatry (2006) 0.78
Chronic mentally ill individuals reentering the community after hospitalization. Phase II: The urban experience. J Psychiatr Ment Health Nurs (1999) 0.78
Cost analysis of schizophrenia treatment with second-generation antipsychotic medications in North Carolina's Medicaid program. J Am Pharm Assoc (2003) (2007) 0.77
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry (2003) 3.85
Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav (2008) 1.85
In the absence of a central venous catheter, risk of venous thromboembolism is low in critically injured children, adolescents, and young adults: evidence from the National Trauma Data Bank. Pediatr Crit Care Med (2011) 1.64
The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res (2003) 1.58
Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry (2015) 1.55
Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord (2010) 1.54
A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord (2009) 1.42
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull (2008) 1.38
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia (2007) 1.35
Methodological issues in negative symptom trials. Schizophr Bull (2011) 1.28
Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs (2011) 1.25
A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia. Psychiatry (Edgmont) (2010) 1.18
Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord (2009) 1.15
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. Am J Psychiatry (2004) 1.12
Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav (2009) 1.12
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol (2010) 1.11
Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med (2011) 1.09
Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factor. Clin Schizophr Relat Psychoses (2011) 1.00
Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord (2010) 0.98
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord (2009) 0.97
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biol Psychiatry (2003) 0.96
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol (2010) 0.93
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol (2012) 0.92
The inpatient burden of abdominal and gynecological adhesiolysis in the US. BMC Surg (2011) 0.92
Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res (2010) 0.92
Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res (2009) 0.91
Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. Int Clin Psychopharmacol (2014) 0.90
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatr Dis Treat (2012) 0.88
Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci (2012) 0.87
Onset and persistence of antipsychotic response in patients with schizophrenia. J Clin Psychopharmacol (2009) 0.86
The direct economic burden of blunt and penetrating trauma in a managed care population. J Trauma (2007) 0.86
A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant. Pharm Stat (2007) 0.85
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry (2013) 0.85
Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide. Schizophr Res (2003) 0.85
Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response. PLoS One (2012) 0.84
Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial. Ther Adv Psychopharmacol (2011) 0.84
Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary. Health Qual Life Outcomes (2008) 0.83
Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC Psychiatry (2011) 0.83
Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs. World J Surg Oncol (2012) 0.82
Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. Int Clin Psychopharmacol (2015) 0.82
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res (2013) 0.82
Management of antipsychotic treatment discontinuation and interruptions using model-based simulations. Clin Pharmacol (2012) 0.82
Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol (2012) 0.81
Potential reduction in neural tube defects associated with use of Metafolin-fortified oral contraceptives in the United States. Am J Obstet Gynecol (2011) 0.81
Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder. Appl Health Econ Health Policy (2014) 0.80
Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry (2011) 0.80
Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophr Res (2011) 0.80
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. Neuropsychiatr Dis Treat (2013) 0.80
Burden of schizophrenia on selected comorbidity costs. Expert Rev Pharmacoecon Outcomes Res (2014) 0.80
Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. Schizophr Res (2012) 0.80
Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea. Curr Med Res Opin (2015) 0.79
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. BMC Psychiatry (2014) 0.79
Study Site Experiences and Attitudes Toward Prospective Assessments of Suicidal Ideation and Behavior in Clinical Trials: Results of an Internet-based Survey. Innov Clin Neurosci (2013) 0.79
Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale. Innov Clin Neurosci (2012) 0.79
Variations in blood pressure and lipid goal attainment in primary care. Curr Med Res Opin (2013) 0.79
The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry (2015) 0.78
Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression. J Affect Disord (2013) 0.78
Association between obesity and therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia. Postgrad Med (2014) 0.78
Muscular dystrophy-related hospitalizations among male pediatric patients in the United States. Hosp Pract (1995) (2015) 0.77
Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment. Psychiatr Serv (2014) 0.77
Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia. Pharmacogenet Genomics (2015) 0.77
Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia. J Pharm Health Serv Res (2013) 0.77
Clinical characteristics and resource utilization of patients with bipolar disorder who have frequent psychiatric interventions. J Med Econ (2010) 0.77
Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting. Postgrad Med (2014) 0.77
Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol (2012) 0.76
Wayne Fenton's impact on industry. Schizophr Bull (2007) 0.76
Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Hum Vaccin (2011) 0.76
Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophr Res (2013) 0.75
Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder. J Clin Psychopharmacol (2016) 0.75
Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose. Neuropsychiatr Dis Treat (2013) 0.75
Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder. J Nerv Ment Dis (2017) 0.75
Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia. Int Clin Psychopharmacol (2016) 0.75
Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorder. Innov Clin Neurosci (2011) 0.75
Genome-wide association study of paliperidone efficacy. Pharmacogenet Genomics (2017) 0.75
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry (2012) 0.75
Point-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting. Hosp Pract (1995) (2014) 0.75
A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Manag Care Interface (2005) 0.75
Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD. Manag Care (2011) 0.75
Comments on "Presidential address: advocacy as leadership". Am J Psychiatry (2007) 0.75
Perceptions and prescribing considerations among US psychiatrists regarding drug-drug interactions associated with oral atypical antipsychotics. Curr Med Res Opin (2010) 0.75
Bayesian data analysis in observational comparative effectiveness research: rationale and examples. J Comp Eff Res (2013) 0.75
Regional differences in the prevalence, treatment and control of hypertension and dyslipidemia in US urban Hispanic populations participating in health screening events. Ethn Dis (2008) 0.75
Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL. Curr Med Res Opin (2004) 0.75